Why the study?
Does control of anticoagulant therapy by activated partial thromboplastin time compared to one-stage prothrombin time affect the incidence of bleeding in patients on anticoagulant therapy?
Does control of anticoagulant therapy by activated partial thromboplastin time compared to one-stage prothrombin time affect the incidence of bleeding in patients on anticoagulant therapy?
Answers are grounded in this paper and cite their sources.
One-stage prothrombin time and activated partial thromboplastin time are comparable in terms of bleeding incidence for monitoring anticoagulant therapy, though prothrombin time may offer practical advantages.
A prospective, randomized trial is described in which the usefulness of two tests in the control of anticoagulant therapy is compared. Fifty-two patients were controlled by the one-stage prothrombin time and 55 by the activated partial thromboplastin time. There was no significant difference in the incidence of bleeding between the two groups. When bleeding did occur, it was more often reflected by prolongation of the prothrombin time than of the activated partial thromboplastin time. The prothrombin time was found to have some practical advantages over the activated partial thromboplastin time.
No takes yet. Share an insight, caveat, or question.
Pearce et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: